3/20
08:00 am
mist
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
Medium
Report
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
3/17
11:20 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
3/13
07:08 am
mist
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Medium
Report
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
3/4
08:00 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
09:31 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
2/27
08:00 am
mist
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
Medium
Report
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
2/19
08:00 am
mist
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Medium
Report
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
2/11
08:41 am
mist
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 [Yahoo! Finance]
2/11
08:00 am
mist
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
Low
Report
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
1/28
08:00 am
mist
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
Medium
Report
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
1/27
08:02 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
1/7
09:28 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Canadian Business Journal (Canada)]
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Canadian Business Journal (Canada)]
1/7
08:35 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/7
08:00 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)